search
Back to results

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé)

Primary Purpose

Hematologic Cancers, Solid Tumors, Metastatic Cancer

Status
Active
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Crizotinib
Sponsored by
UNICANCER
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hematologic Cancers focused on measuring metastatic or unresectable locally advanced malignancies., genomic alterations., biological crizotinib targets (ALK, MET, ROS1, RON, AXL).

Eligibility Criteria

1 Year - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion:

  • Male and female ≥ 1 year of age
  • unresectable locally advanced or metastatic malignant tumor of any histological type (but NSCLC with an ALK translocation) and not amenable to any other validated therapeutic option. ( for pediatrics a relapse after a first well-conducted standard treatment or a situation without any standard treatment and a survival <10%).
  • one proven specific alterations among ALK, MET, RON and ROS1 genes determined on the primary and/or the metastatic lesion
  • Measurable disease according to RECIST 1.1
  • For patients with primary cerebral tumors (adults or children), measurable disease defined by bi-dimensional measurements : two perpendicular diameters of at least 10 mm on CT or MRI scan, outside of a previously radiated field within the last 3 months, to observe pseudoprogression
  • hematologic function (ANC ≥ 1.0x10⁹/L, platelets ≥ 75x10⁹/L, platelets ≥ 50x10⁹/L for ALCL with bone marrow involved ; platelets ≥ 100x10⁹/L for primary or secondary cerebral tumors; Hb ≥ 8g/L), renal function (creat cl ≥ 50 mL/min Cockcroft and Gault) and hepatic function (serum bilirubin ≤ 1.5x ULN unless due to Gilbert's syndrome ; ASAT and ALAT ≤ 5x ULN if liver metastasis or ≤ 3x ULN if liver metastasis with advanced fibrosis (FibroTest>0.48) or ≤ 3x ULN without liver metastasis)
  • normal values for calcium, magnesium and potassium levels
  • able to swallow and retain oral medication
  • ECOG Performance Status of 0 to 2, or Karnofsky scale > 50 % or Lansky Play scale (< 12 years) > 50%, (for CNS tumors, the neurological deficiency due to the disease itself)
  • Life expectancy ≥ 3 months

Exclusion :

  • NSCLC patients ALK translocations
  • Patient eligible for a clinical trial with an anticancer drug (including crizotinib) targeting the same molecular alteration open to accrual in France.
  • alteration limited to an overexpression of ALK, MET, RON, ROS1 or any other crizotinib-target. Only patients with ALCL are eligible if ALK is positive by immunohistochemistry
  • Patients with primary or secondary central nervous system disease
  • Previous treatment with crizotinib
  • Major surgery or tumor embolization within 4 weeks and minor surgery within 2 weeks prior to the initiation of the study drug. Brain surgery is excluded within 4 weeks prior to starting crizotinib for primary or secondary cerebral tumors

  • Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to :

    • Within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack
    • Ongoing congestive heart failure
    • Congenital long QT syndrome
    • Heart rate ≤ 45 beats/minute
    • Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, or with QTcF interval >470 msec
    • For patients with a cerebral disease (primary or secondary) : uncontrolled hypertension [defined as SBP of ≥ 140 mmHg or DBP of ≥ 90mmHg]
    • extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not prior radiation pneumonitis
    • Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function
    • Carcinomatous meningitis or leptomeningeal disease
    • HIV-positive, active hepatitis A, B or C, or latent hepatitis B or C, or any other uncontrolled infection
    • Other severe acute or chronic medical or psychiatric conditions, or end stage renal disease on hemodialysis or laboratory abnormalities
    • For patients with a cerebral disease, detection on the MRI or the CTscan of a real arteriovenous malformation, or an untreated intracranial aneurysm, or a cavernous angioma, or an amyloid angiopathy, or any new or significant (≥ grade 2) intratumoral bleeding other than microbleeds on T2* weighted MRI in the previous 14 days before treatment initiation, or a recent and untreated subdural effusion.
  • Patients using non-substitutable drugs that are potent CYP3A4 inhibitors, or potent CYP3A4 inducers
  • Patients using non-substitutable drugs that are CYP3A4 substrates with narrow therapeutic indices
  • Patients with cerebral disease using anti-platelet drugs or anticoagulant agents are not eligible if those treatments can not be stopped 7 days before day1.
  • Patients with altered mental status or with psychological, familial, sociological or geographical condition potentially hampering compliance
  • Individual deprived of liberty or placed under the authority of a tutor.

Sites / Locations

  • Gustave Roussy

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CRIZOTINIB

Arm Description

All eligible patients entering the study will receive oral crizotinib as monotherapy

Outcomes

Primary Outcome Measures

The efficacy of crizotinib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the crizotinib target genes, per cohort, per pathology, and per target.
Anti-tumor activity of crizotinib, as the primary objective of the trial, will be carried out by the determination of the objective response assessed in each cohort defined by a pathology associated with a crizotinib target alteration. The objective response is defined as either a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The objective response after 2 cycles (8 weeks) will be reported to define a success in the 2-stage design.

Secondary Outcome Measures

The safety profile of crizotinib.
Toxicities will be assessed by clinical and paraclinical examinations at every scheduled visit during the whole treatment period and the post-treatment follow-up period (around 2.5 years) This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.
Disease control rate
Disease Control Rate will be the percentage of patients with a CR, PR or Stable Disease (SD) according to RECIST at the end of cycle 2 (8 weeks) and at the end of cycle 4 (16 weeks) in the group of patients evaluable for response
response duration
Response duration will be the time interval between the date that the criteria of CR/PR (whichever is first recorded) are met for the first time and the first date of documented re-appearance of the disease (recurrence, progression or death). If neither event has been observed, then the patient is censored at the date of the last follow up examination.
Progression-free survival
Progression-free survival will be the time interval between the date of registration and the day of first documented sign of disease progression (first day when RECIST criteria of progression are met) or day of death whatever the cause (events). If neither event has been observed, then the patient is censored at the date of the last follow up examination.
Overall survival
Overall survival will be the time interval between the date of registration and the date of death, whatever the cause of death. Patients still alive at follow-up are censored at the date of last follow up.

Full Information

First Posted
October 16, 2013
Last Updated
September 5, 2022
Sponsor
UNICANCER
Collaborators
National Cancer Institute, France, Fondation ARC, Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT02034981
Brief Title
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1
Acronym
AcSé
Official Title
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 2013 (Actual)
Primary Completion Date
June 2019 (Actual)
Study Completion Date
January 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
UNICANCER
Collaborators
National Cancer Institute, France, Fondation ARC, Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a biology driven, trans-tumoral, multicentric phase II trial assessing the efficacy and the safety of the targeted agent crizotinib as a monotherapy in 23 cohorts of patients with identified activating molecular alterations in the crizotinib target genes. A cohort is defined by a pathology and a crizotinib-target alteration (eg gastric cancer with MET amplification). For each cohort a two-stage design will be implemented. In the situation where expected accrual allows for a sufficient number of patients to be accrued, the alpha and beta errors will be fixed at 10%. However, in very rare diseases, such as inflammatory myofibroblastic tumor (IMT), neuroblastoma, glioblastoma, and rhabdomyosarcoma (RMS), it is anticipated that the target number may not be achievable in a reasonable timeframe; for these cohorts, the alpha and beta errors will be fixed at 15%. Consequently three different statistical designs will be a priori considered according to the expected response rate and incidence.
Detailed Description
Twenty cohorts are identified, a cohort being defined as [one pathology, one target alteration] such as [gastric cancer with MET amplification (6%)]. One cohort will be dedicated to miscellaneous, very rare pediatric diseases identified through INCa platforms or pan-genome programs (e.g. MOSKIDO, IGR) and will recruit up to 10 patients. Two cohorts will be dedicated to a couple of diseases harbouring at least one specific alteration in one crizotinib target, same or different from those listed above, e.g. in AXL gene, arising from pan-genome trials. ALCL, adults and children, ALK-translocated Colorectal cancer, adults, ALK-translocated Colorectal cancer, adults, MET amplified Colorectal cancer, adults, MET mutated NSCLC, adults, MET amplified NSCLC, adults, ROS1-translocated Breast cancer, adults, ALK-translocated Gastric cancer, adults, MET amplified Cholangiocarcinoma, adults, ROS1-translocated Ovarian cancer, adults, MET amplified Clear cell renal cell carcinoma, adults, ALK-translocated Clear cell renal cell carcinoma, adults, ALK-amplified Papillary renal cell carcinoma, adults, MET mutated (+ MET amplified) Hepatocarcinoma, adults, MET amplified Neuroblastoma, adults and children, ALK-amplified + ALK mutated IMT, adults and children, ALK-translocated Rhabdomyosarcoma (alveolar and embryonal), adults and children, ALK-amplified Glioblastoma, adults, MET amplified. This cohort will only be open after amendment Anaplastic thyroid cancer, adults, ALK mutated Thyroid cancer (follicular + medullary + papillary), adults, MET mutated Miscellaneous rare pediatric diseases associated to at least one specific alteration in one crizotinib target, same or different from those listed above One another pathology associated to at least one specific alteration in one crizotinib target, same or different from those listed above. One another pathology associated to at least one specific alteration in one crizotinib target, same or different from those listed above.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hematologic Cancers, Solid Tumors, Metastatic Cancer
Keywords
metastatic or unresectable locally advanced malignancies., genomic alterations., biological crizotinib targets (ALK, MET, ROS1, RON, AXL).

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
246 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CRIZOTINIB
Arm Type
Experimental
Arm Description
All eligible patients entering the study will receive oral crizotinib as monotherapy
Intervention Type
Drug
Intervention Name(s)
Crizotinib
Other Intervention Name(s)
XALKORI
Intervention Description
Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops. -250 mg twice daily for adults ≥ 18 years of age 280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL). 165 mg/m² twice daily for ALCL patients aged from 1 to 17.
Primary Outcome Measure Information:
Title
The efficacy of crizotinib as a single agent across diverse type of tumors guided by the presence of identified activating molecular alterations in the crizotinib target genes, per cohort, per pathology, and per target.
Description
Anti-tumor activity of crizotinib, as the primary objective of the trial, will be carried out by the determination of the objective response assessed in each cohort defined by a pathology associated with a crizotinib target alteration. The objective response is defined as either a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. The objective response after 2 cycles (8 weeks) will be reported to define a success in the 2-stage design.
Time Frame
Determined after 8 weeks (2 cycles) of treatment
Secondary Outcome Measure Information:
Title
The safety profile of crizotinib.
Description
Toxicities will be assessed by clinical and paraclinical examinations at every scheduled visit during the whole treatment period and the post-treatment follow-up period (around 2.5 years) This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting.
Time Frame
Safety profile will be assessed during the whole treatment period (6 months expected in average) followed by a 2-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart
Title
Disease control rate
Description
Disease Control Rate will be the percentage of patients with a CR, PR or Stable Disease (SD) according to RECIST at the end of cycle 2 (8 weeks) and at the end of cycle 4 (16 weeks) in the group of patients evaluable for response
Time Frame
After 8 weeks (2 cycles) and 16 weeks (4 cycles) of treatment
Title
response duration
Description
Response duration will be the time interval between the date that the criteria of CR/PR (whichever is first recorded) are met for the first time and the first date of documented re-appearance of the disease (recurrence, progression or death). If neither event has been observed, then the patient is censored at the date of the last follow up examination.
Time Frame
interval between the objective response (CR or PR) and time of progression, recurrence or death
Title
Progression-free survival
Description
Progression-free survival will be the time interval between the date of registration and the day of first documented sign of disease progression (first day when RECIST criteria of progression are met) or day of death whatever the cause (events). If neither event has been observed, then the patient is censored at the date of the last follow up examination.
Time Frame
from registration until time of disease progression or death
Title
Overall survival
Description
Overall survival will be the time interval between the date of registration and the date of death, whatever the cause of death. Patients still alive at follow-up are censored at the date of last follow up.
Time Frame
from registration until date of death

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion: Male and female ≥ 1 year of age unresectable locally advanced or metastatic malignant tumor of any histological type (but NSCLC with an ALK translocation) and not amenable to any other validated therapeutic option. ( for pediatrics a relapse after a first well-conducted standard treatment or a situation without any standard treatment and a survival <10%). one proven specific alterations among ALK, MET, RON and ROS1 genes determined on the primary and/or the metastatic lesion Measurable disease according to RECIST 1.1 For patients with primary cerebral tumors (adults or children), measurable disease defined by bi-dimensional measurements : two perpendicular diameters of at least 10 mm on CT or MRI scan, outside of a previously radiated field within the last 3 months, to observe pseudoprogression hematologic function (ANC ≥ 1.0x10⁹/L, platelets ≥ 75x10⁹/L, platelets ≥ 50x10⁹/L for ALCL with bone marrow involved ; platelets ≥ 100x10⁹/L for primary or secondary cerebral tumors; Hb ≥ 8g/L), renal function (creat cl ≥ 50 mL/min Cockcroft and Gault) and hepatic function (serum bilirubin ≤ 1.5x ULN unless due to Gilbert's syndrome ; ASAT and ALAT ≤ 5x ULN if liver metastasis or ≤ 3x ULN if liver metastasis with advanced fibrosis (FibroTest>0.48) or ≤ 3x ULN without liver metastasis) normal values for calcium, magnesium and potassium levels able to swallow and retain oral medication ECOG Performance Status of 0 to 2, or Karnofsky scale > 50 % or Lansky Play scale (< 12 years) > 50%, (for CNS tumors, the neurological deficiency due to the disease itself) Life expectancy ≥ 3 months Exclusion : NSCLC patients ALK translocations Patient eligible for a clinical trial with an anticancer drug (including crizotinib) targeting the same molecular alteration open to accrual in France. alteration limited to an overexpression of ALK, MET, RON, ROS1 or any other crizotinib-target. Only patients with ALCL are eligible if ALK is positive by immunohistochemistry Patients with primary or secondary central nervous system disease Previous treatment with crizotinib Major surgery or tumor embolization within 4 weeks and minor surgery within 2 weeks prior to the initiation of the study drug. Brain surgery is excluded within 4 weeks prior to starting crizotinib for primary or secondary cerebral tumors Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, such as, but not limited to : Within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack Ongoing congestive heart failure Congenital long QT syndrome Heart rate ≤ 45 beats/minute Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation of any grade, or with QTcF interval >470 msec For patients with a cerebral disease (primary or secondary) : uncontrolled hypertension [defined as SBP of ≥ 140 mmHg or DBP of ≥ 90mmHg] extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not prior radiation pneumonitis Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function Carcinomatous meningitis or leptomeningeal disease HIV-positive, active hepatitis A, B or C, or latent hepatitis B or C, or any other uncontrolled infection Other severe acute or chronic medical or psychiatric conditions, or end stage renal disease on hemodialysis or laboratory abnormalities For patients with a cerebral disease, detection on the MRI or the CTscan of a real arteriovenous malformation, or an untreated intracranial aneurysm, or a cavernous angioma, or an amyloid angiopathy, or any new or significant (≥ grade 2) intratumoral bleeding other than microbleeds on T2* weighted MRI in the previous 14 days before treatment initiation, or a recent and untreated subdural effusion. Patients using non-substitutable drugs that are potent CYP3A4 inhibitors, or potent CYP3A4 inducers Patients using non-substitutable drugs that are CYP3A4 substrates with narrow therapeutic indices Patients with cerebral disease using anti-platelet drugs or anticoagulant agents are not eligible if those treatments can not be stopped 7 days before day1. Patients with altered mental status or with psychological, familial, sociological or geographical condition potentially hampering compliance Individual deprived of liberty or placed under the authority of a tutor.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilles VASSAL
Organizational Affiliation
Gustave Roussy, Villejuif
Official's Role
Principal Investigator
Facility Information:
Facility Name
Gustave Roussy
City
Villejuif
State/Province
Ile De France
ZIP/Postal Code
94805
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
33847874
Citation
Aparicio T, Cozic N, de la Fouchardiere C, Meriaux E, Plaza J, Mineur L, Guimbaud R, Samalin E, Mary F, Lecomte T, Gomez-Roca C, Haineaux PA, Gratet A, Selves J, Menu Y, Colignon N, Johnson L, Legrand F, Vassal G. The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSe-Crizotinib Program. Target Oncol. 2021 May;16(3):381-388. doi: 10.1007/s11523-021-00811-8. Epub 2021 Apr 13.
Results Reference
derived
PubMed Identifier
31584608
Citation
Moro-Sibilot D, Cozic N, Perol M, Mazieres J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, Barlesi F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSe phase II trial. Ann Oncol. 2019 Dec 1;30(12):1985-1991. doi: 10.1093/annonc/mdz407.
Results Reference
derived

Learn more about this trial

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

We'll reach out to this number within 24 hrs